SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay

Mostrar otras versiones (1)

Serosurveillance studies are critical for estimating SARS-CoV-2 transmission and immunity, but interpretation of results is currently limited by poorly defined variability in the performance of antibody assays to detect seroreactivity over time in individuals with different clinical presentations. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Peluso, Michael J., Takahashi, Saki, Hakim, Jill, Kelly, J. Daniel, Torres, Leonel, Iyer, Nikita S., Turcios, Keirstinne, Janson, Owen, Munter, Sadie E., Thanh, Cassandra, Nixon, Christopher C., Hoh, Rebecca, Tai, Viva, Fehrman, Emily A., Hernandez, Yanel, Spinelli, Matthew A., Gandhi, Monica, Palafox, Mary-Ann, Vallari, Ana, Rodgers, Mary A., Prostko, John, Hackett, John, Trinh, Lan, Wrin, Terri, Petroplolous, Christos J., Chiu, Charles Y., Norris, Philip J., DiGermanio, Clara, Stone, Mars, Busch, Michael P., Elledge, Susanna K., Zhou, Xin X., Wells, James A., Shu, Albert, Kurtz, Theodore W., Pak, John E., Wu, Wesley, Burbelo, Peter D., Cohen, Jeffrey I., Rutishauser, Rachel L., Martin, Jeffrey N., Deeks, Steven G., Henrich, Timothy J., Rodriguez-Barraquer, Isabel, Greenhouse, Bryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941652/
https://www.ncbi.nlm.nih.gov/pubmed/33688675
http://dx.doi.org/10.1101/2021.03.03.21251639
Mostrar todas las versiones(2)

Ejemplares similares